Physician profile
George Dodds
NPI 1225005754
$3,266.05
in general payments reported to CMS, 2019-2025
19 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.77 · 2020: $16.77 · 2021: $88.40 · 2022: $544 · 2023: $861 · 2024: $828 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,093.86 | 2022-2025 | |
| Heartflow, INC. | $677.72 | 2022-2025 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.76 | 2020-2025 | Lifevest |
| Abiomed | $210.58 | 2023-2025 | Impella |
| Boston Scientific Corporation | $149.25 | 2023 | Watchman Access System |
| Abbott Laboratories | $144.44 | 2019-2022 | |
| Stryker Corporation | $136.01 | 2023 | Mako |
| Amgen INC. | $104.27 | 2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $98.08 | 2024 | Arcalyst |
| Medtronic, INC. | $91.16 | 2025 | Symplicity G3 |
| Kestra Medical Technology Services, INC. | $75.31 | 2023-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.05 | 2022-2024 | Jardiance |
| Biotronik INC. | $44.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.70 | 2023-2025 | Farxiga |
| Scpharmaceuticals INC. | $38.17 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.43 | 2022 | |
| Impulse Dynamics (USA) INC. | $19.32 | 2024 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $14.68 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dodds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.